Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Regression of renal amyloid deposits by VAD therapy plus autologous stem cell transplantation in a patient with primary AL amyloidosis.

Toriu N, Sawa N, Hiramatsu R, Mizuno H, Ikuma D, Sekine A, Hayami N, Sumida K, Yamanouchi M, Hasegawa E, Hoshino J, Takaichi K, Wake A, Ohashi K, Fujii T, Ubara Y.

CEN Case Rep. 2019 Sep 14. doi: 10.1007/s13730-019-00416-1. [Epub ahead of print]

2.

Renal-Limited Thrombotic Microangiopathy due to Bevacizumab Therapy for Metastatic Colorectal Cancer: A Case Report.

Toriu N, Sekine A, Mizuno H, Hasegawa E, Yamanouchi M, Hiramatsu R, Hayami N, Hoshino J, Kawada M, Suwabe T, Sumida K, Sawa N, Takaichi K, Ohashi K, Fujii T, Matoba S, Ubara Y.

Case Rep Oncol. 2019 Jun 4;12(2):391-400. doi: 10.1159/000500716. eCollection 2019 May-Aug.

3.

Increase of 1,25 dihydroxyvitamin D in sarcoidosis patients with renal dysfunction.

Toriu N, Sumida K, Oguro M, Oshima Y, Mizuno H, Hasegawa E, Suwabe T, Kawada M, Ueno T, Hayami N, Sekine A, Hiramatsu R, Yamanouchi M, Hoshino J, Sawa N, Takaichi K, Ohashi K, Kinowaki K, Fujii T, Date R, Ubara Y.

Clin Exp Nephrol. 2019 Oct;23(10):1202-1210. doi: 10.1007/s10157-019-01760-3. Epub 2019 Jun 25.

PMID:
31240503
4.

Long-term outcome of biopsy-proven cholesterol crystal embolism.

Toriu N, Sumida K, Mizuno H, Hasegawa E, Suwabe T, Kawada M, Ueno T, Hayami N, Sekine A, Hiramatsu R, Yamanouchi M, Hoshino J, Sawa N, Takaichi K, Ohashi K, Fujii T, Ubara Y.

Clin Exp Nephrol. 2019 Oct;23(10):1181-1187. doi: 10.1007/s10157-019-01749-y. Epub 2019 Jun 3.

PMID:
31161263
5.

Brown tumor diagnosed three years after parathyroidectomy in a patient with nail-patella syndrome: A case report.

Toriu N, Ueno T, Mizuno H, Sekine A, Hayami N, Hiramatsu R, Sumida K, Yamanouchi M, Hasegawa E, Suwabe T, Hoshino J, Sawa N, Takaichi K, Fujii T, Hasegawa T, Amizuka N, Yanagita M, Ubara Y.

Bone Rep. 2018 Dec 10;10:100187. doi: 10.1016/j.bonr.2018.100187. eCollection 2019 Jun.

6.

A case of nephrotic syndrome showing contemporary presence of apolipoprotein E2 homozygote glomerulopathy and membranous nephropathy-like findings modified by apolipoprotein E Toyonaka.

Hirashima H, Komiya T, Toriu N, Hara S, Matsunaga A, Saito T, Muso E.

Clin Nephrol Case Stud. 2018 Nov 30;6:45-51. doi: 10.5414/CNCS109509. eCollection 2018.

7.

Renal-limited Cryoglobulinemic Vasculitis: Two Case Reports.

Toriu N, Sawa N, Oguro M, Mizuno H, Oshima Y, Hasegawa E, Sumida K, Suwabe T, Kawada M, Ueno T, Hayami N, Sekine A, Hiramatsu R, Yamanouchi M, Hoshino J, Takaichi K, Ohashi K, Fujii T, Yanagita M, Ubara Y.

Intern Med. 2018;57(13):1879-1886. doi: 10.2169/internalmedicine.0131-17. Epub 2018 Jul 1.

8.

Everolimus Reduces the Size of Tuberous Sclerosis Complex-Related Huge Renal Angiomyolipomas Exceeding 20 cm in the Longest Diameter.

Toriu N, Mizuno H, Sawa N, Sumida K, Suwabe T, Hayami N, Sekine A, Yamanouchi M, Hoshino J, Takaichi K, Yanagita M, Fujimaru T, Mori T, Sohara E, Uchida S, Ubara Y.

Case Rep Oncol. 2018 May 2;11(2):258-267. doi: 10.1159/000488704. eCollection 2018 May-Aug.

9.

Transcatheter Arterial Embolization Therapy for Huge Renal Cysts: Two Case Reports.

Toriu N, Hoshino J, Kobori S, Watanabe S, Oguro M, Oshima Y, Hiramatsu R, Mizuno H, Ikuma D, Sekine A, Hayami N, Sumida K, Yamanouchi M, Hasegawa E, Sawa N, Takaichi K, Yanagita M, Fujimaru T, Sohara E, Uchida S, Ubara Y.

Case Rep Nephrol Dial. 2018 Apr 27;8(1):82-89. doi: 10.1159/000489088. eCollection 2018 Jan-Apr.

10.

Preservation of renal function by intensive glycemic control.

Toriu N, Yamanouchi M, Hiramatsu R, Hayami N, Hoshino J, Sekine A, Kawada M, Hasegawa E, Suwabe T, Sumida K, Ueno T, Sawa N, Ohashi K, Fujii T, Takaichi K, Yanagita M, Kobayasi T, Ubara Y.

Endocrinol Diabetes Metab Case Rep. 2018 Jan 8;2018. pii: 17-0136. doi: 10.1530/EDM-17-0136. eCollection 2018.

11.
12.

Keratinocyte growth inhibition by high-dose epidermal growth factor is mediated by transforming growth factor beta autoinduction: a negative feedback mechanism for keratinocyte growth.

Yamasaki K, Toriu N, Hanakawa Y, Shirakata Y, Sayama K, Takayanagi A, Ohtsubo M, Gamou S, Shimizu N, Fujii M, Miyazono K, Hashimoto K.

J Invest Dermatol. 2003 Jun;120(6):1030-7.

13.

Effects of lomerizine, a novel Ca2+ channel blocker, on the normal and endothelin-1-disturbed circulation in the optic nerve head of rabbits.

Toriu N, Sasaoka M, Shimazawa M, Sugiyama T, Hara H.

J Ocul Pharmacol Ther. 2001 Apr;17(2):131-49.

PMID:
11324981
14.

Lomerizine, a Ca2+ channel blocker, reduces glutamate-induced neurotoxicity and ischemia/reperfusion damage in rat retina.

Toriu N, Akaike A, Yasuyoshi H, Zhang S, Kashii S, Honda Y, Shimazawa M, Hara H.

Exp Eye Res. 2000 Apr;70(4):475-84.

PMID:
10865996
15.

Supplemental Content

Support Center